Genitope Corp About
Genitope Genitope Corporation is a biotechnology company
focused on the research and development of novel immunotherapies for the treatment
of cancer. Immunotherapy products are designed to utilize the immune system to
combat diseases such as cancer. Genitipes lead product candidate, MyVax® Personalized
Immunotherapy (previously referred to as GTOP-99) is currently in a pivotal Phase
3 trial for the treatment of follicular non-Hodgkin's lymphoma (f-NHL). Genitope's lead product candidate,
MyVax® Personalized Immunotherapy (previously referred to as GTOP-99),
is an investigational treatment based on the unique genetic makeup of a patient's
tumor and is designed to activate a patient's immune system to identify and attack
cancer cells. This product is currently being evaluated in patients with follicular
non-Hodgkin's lymphoma
(f-NHL). More
on Genitope